相关实验视频

Updated: Jun 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

氨基多碳酸氨基酸修饰的阿比拉特衍生物作为潜在的可注射的抗前列腺癌药物

Na Zhu¹, Shuai Meng², Lina Mao³

¹Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, PR China; Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, PR China.

Bioorganic chemistry

|September 21, 2024

概括

与阿比拉相比,一种新的注射性前列腺癌药物,阿比拉二乙二胺酸 (Abi-DTPA),显示出更好的有效性和更低的毒性. 这种衍生物向CYP17,抑制癌细胞生长并促进细胞亡.

科学领域:

药理学药理学是指药理学的学科.
在瘤学瘤学.
药用化学医学化学

背景情况:

阿比拉 (Abi) 是一种细胞染色体P450 C17 (CYP17) 抑制剂,通过降低雄激素合成,有效对抗前列腺癌.
艾比的临床应用受到溶解性差,生物可用性低和有毒副作用的限制.

研究的目的:

开发水溶性和注射性阿比拉衍生物.
评估这些衍生物的抗增殖作用,作用机制,体内抗瘤活性,药理动力学和毒性.

主要方法:

通过引入氨基聚碳酸氨基酸来合成水溶性Abi衍生物.
在体外和体内对抗瘤活性,细胞迁移,入侵和线粒体膜潜力的评估.
涉及CYP17向和与亡相关的蛋白质表达分析的机制研究.
静脉注射后的药理动力学和毒性评估.

主要成果:

与Abi相比,衍生品Abi-DTPA在体外和体内表现出更高的抗瘤活性.
阿比-DTPA降低了癌细胞的迁移,入侵和线粒体膜潜力.
机理学研究证实了CYP17的抑制和亡标志物的增加 (切割的caspase9,PARP,caspase3).
在静脉注射后,Abi-DTPA表现出有利的药理动力学和较低的毒性.

结论:

阿比-DTPA是前列腺癌治疗的有前途的注射剂.
阿比-DTPA的增强溶解度和有针对性的作用提高了治疗潜力.
进一步的研究支持Abi-DTPA作为一种新的抗前列腺癌治疗方法.

关键词:

在水中溶解的阿比拉特龙衍生物.氨基多碳酸氨基酸的氨基多碳酸.细胞氧化酶的作用是:前列腺癌是前列腺癌.毒性的毒性毒性的毒性

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Prodrugs

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...